Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — H1 2022 Earnings Presentation
11 slides from Zealand Pharma A/s's earnings presentation, Aug 11, 2022
Slide 1: 6M 2022 Interim report
6M 2022 Interim report Zealand Pharma 11 August 2022
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, that provide Zealand Pharma’s expectations or forecasts of future events regarding the research, development and commerciali
Slide 3: Short-term priorities set the scene for Zealand's transformation (1-3)
Short-term priorities set the scene for Zealand’s transformation 1 2 3 Implementing Executing Strengthening operational efficiencies commercial partnerships the balance sheet and cost reductions V-Go sale to MannKind Debt restructuring Delisting ADSs $40M USD direct issue Zegalogue partnership 3 1H
Slide 4: Short-term priorities set the scene for Zealand's transformation (4-6)
Short-term priorities set the scene for Zealand’s transformation 4 5 6 Topline readouts Targeting hypoglycemia Advancing a portfolio in and NDA preparations on with dasiglucagon obesity key late-stage programs CHI Phase 3 results Mini-dose pen Phase 2 (IIT) Dapiglutide (GLP-1/GLP-2) type 1 diabetes
Slide 5: Phase program of dasiglucagon in children with congenital hyperinsulinism (CHI)
Phase 3 program of dasiglucagon in children with congenital hyperinsulinism (CHI) Trial 109 – Rates of Hypoglycemia Trial 103 – IV Glucose Infusion Rate (Aged 3 months to 12 years) (Aged 7 days to 12 months) 20 60 Rates of Hypoglycemia by CGM 50 Standard of Care (SoC) Dasiglucagon + SoC 15 p=0.0037
Slide 6: Our pipeline addresses significant unmet medical needs across several diseases
Our pipeline addresses significant unmet medical needs across several diseases and provides near-term value triggers Product Candidate* Preclinical Phase 1 Phase 2 Phase 3 Registration diabetes Dasiglucagon Bi-Hormonal Artificial Pancreas Pump Type 1 Type 1 Diabetes management Dasiglucagon Low-Dose
Slide 7: Income statement
Income statement DKK million 1H 2022 1H 2021 Revenue 43.5 42.3 Gross margin 38.2 30.6 Research and Development expenses -304.2 -284.4 Sales and Marketing Expenses -77.4 -170.6 Administrative Expenses -121.0 -127.5 Net Operating Expenses -502.6 -582.4 Other Operating Items -74.8 -0.0 Total Operating
Slide 8: Balance sheet allows for continued investments
Balance sheet allows for continued investments Total Operating Expenses as of June 30, 2022 Cash position as of June, 2022 DKK 577.4 million / USD $80.6 million DKK 864.4 million / USD $120.7 million DKK thousand DKK thousand 1.400.000 1.600.000 1.200.000 1.400.000 1.000.000 1.200.000 1.000.000 800.
Slide 9: 2022 financial guidance
2022 financial guidance Net product revenue from the sales of Zegalogue is expected to be DKK 11.5 million +/- 10%. This is a reduction of DKK 7.5 million from our updated guidance issued on May 12, 2022. With the completion of the Asset Purchase Agreement for V-Go with MannKind Corporation, the com
Slide 10: 2022 Major Upcoming Events & Strategic Objectives
2022 Major Upcoming Events & Strategic Objectives • Report EASE-SBS1 glepaglutide Phase 3 trial topline results – 3Q 2022 • Present BI 456906 Phase 2 trial results in type 2 diabetes – 2H 2022 • Update Phase 1 SAD and start MAD for amylin analog ZP8396 in obesity – 2H 2022 • Execute commercial partn
Slide 11: Q&A session
Q&A session• 1H 2022 presentation 11 August 2022 11